OncoAlert Top FDA Approvals for Solid Cancers in 2022

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

OncoAlert Top FDA Approvals for Solid Cancers in 2022

By OncoAlert FEATURING Gilberto Morgan

175 views

March 1, 2023

Comments 0

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Inaugural Houston Methodist Neal Cancer Center GI Oncology Symposium

Fri, Dec 6, 2024

RENALC-BLADDR-PROSCA 2024

PROSCA 2024 - Hybrid Global Forum on GU Oncology

Thu, Nov 28, 2024

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.1K views

5 months ago

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.1K views

5 months ago

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2.5K views

7 months ago

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.1K views

4 months ago

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views

1 year ago

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views

8 months ago

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

1.6K views

4 months ago

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views

11 months ago

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views

9 months ago

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.5K views

2 months ago

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views

9 months ago

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

2.6K views

9 months ago

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

540 views

1 month ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

2023 Menopause Update

Yale School of Medicine

M. Minkin

9.0K views

1 year ago

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

1.3K views

8 months ago

Year in Review: Lung Cancer

Balazs Halmos

2.6K views

10 months ago

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

721 views

1 month ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

AUTOPLAY

Login

Login

Join VuMedi

OncoAlert Top FDA Approvals for Solid Cancers in 2022

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Recommended

Inaugural Houston Methodist Neal Cancer Center GI Oncology Symposium

PROSCA 2024 - Hybrid Global Forum on GU Oncology

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

The Use of IO Doublet in PD-L1-Negative NSCLC

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

Year in Review: Breast Cancer

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Recent GU Developments and Their Clinical Implications

2023 Menopause Update

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Year in Review: Lung Cancer

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…